CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 135 enrolled
Drug / intervention
Haloperidol +1 moredrug
Likely dose
Haloperidol 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02213900
NCT02213900Phase 4Completed
CompareCT.gov

Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients

Indiana University·interventional·Posted Aug 12, 2014·Updated Apr 13, 2017

In Brief

A Phase 4 clinical trial evaluating Haloperidol and Placebo for Delirium and 4 related conditions. Completed, enrolled 135 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the effectiveness of a preventative low-dose of Haloperidol to prevent delirium in patients undergoing a esophagectomy, pneumonectomy or thoracotomy. Delirium is state of severe confusion and some symptoms include: * Cannot think clearly * Have trouble paying attention * Have a hard time understanding what is going on around them * May see or hear things that are not there. These things seem very real to them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDelirium, Cognitive Impairment, Post-traumatic Stress Disorder, Depression, Anxiety
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 12, 2014
Enrollment StartSep 1, 2013
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.9 years ago

Interventions

Haloperidoldrug

0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days

Placebodrug